Busca avançada
Ano de início
Entree
(Referência obtida automaticamente do Web of Science, por meio da informação sobre o financiamento pela FAPESP e o número do processo correspondente, incluída na publicação pelos autores.)

Exosomes in the serum of Acute Myeloid Leukemia patients induce dendritic cell tolerance: Implications for immunotherapy

Texto completo
Autor(es):
Benites, Bruno Deltreggia [1] ; Santos Duarte, Adriana da Silva [1] ; Figueiredo Longhini, Ana Leda [1] ; Santos, Irene [1] ; Alvarez, Marisa Claudia [1] ; de Morais Ribeiro, Ligia Nunes [2] ; de Paula, Eneida [2] ; Olalla Saad, Sara Teresinha [1]
Número total de Autores: 8
Afiliação do(s) autor(es):
[1] Univ Estadual Campinas, Hematol & Transfus Med Ctr, Rua Carlos Chagas 480, BR-13083970 Campinas, SP - Brazil
[2] Univ Estadual Campinas, Dept Biochem & Tissue Biol, Campinas, SP - Brazil
Número total de Afiliações: 2
Tipo de documento: Artigo Científico
Fonte: Vaccine; v. 37, n. 11, p. 1377-1383, MAR 7 2019.
Citações Web of Science: 1
Resumo

Exosomes may represent an interesting antigenic pulse for new forms of anti-tumor immunotherapy. We evaluated exosomes from serum of patients with acute myeloid leukemia (AML) as an antigenic source for dendritic cells (DC) and the effects upon antitumor cytotoxicity, assessed by the percentage of specific lysis of K562 leukemic cells in co-cultures. Surprisingly, incubation of exosomes with DCs decreased lysis of K562, which may correspond to a mechanism of tumor evasion in vivo. However, when immature DCs were pulsed with exosomes purified from K562 culture supernatants, the lysis of target cells was notably enhanced, associated with a substantial increase in the expression of the maturation marker CD83. Thus, the development of vaccines using patients' exosomes would probably add no benefits to the treatment of AML; alternately, exosomes from cultured cells may represent an effective way for maturing DCs into a cytotoxic phenotype, without the immunosuppression observed with patients' exosomes. (C) 2019 Elsevier Ltd. All rights reserved. (AU)

Processo FAPESP: 11/51959-0 - Biologia das doenças neoplásicas da medula óssea
Beneficiário:Sara Teresinha Olalla Saad
Linha de fomento: Auxílio à Pesquisa - Temático